Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-20

Maybe this is a way to protect the company’s research with big pharma partners. A similar marketing deal with Astodrimer sodium products could allow separation of marketed products and not risk relationship with competing big pharma. Maybe Cheryl is bringing good marketing ideas to the table that can protect the innovation and research. There is good research from Keith Williams about Seres pharmaceuticals in a Substack Feb 24 and the dangers of shorts in pushing commercial failures. He contrasts availability of start up cash in US and Australia. Maybe Pentalion UK can also access cash easier than in Australia and being the home of AZ is a better location than US with Pfizer and FDA go slow on Astodrimer sodium